Access DB# 103983

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: Ben Sackey Examiner #: 73489 Date: 9/15/03
Art Unit: 1624 Phone Number 305-6889 Serial Number: 10/066,801
Mail Box and Bldg/Room Location: CM1 3B19 Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

****

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: _____

Inventors (please provide full names): _____

_____

Earliest Priority Filing Date: _____

**For Sequence Searches Only* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*

Search selected entries in Drug Data reports (File 452)

****

STAFF USE ONLY	Type of Search	Vendors and cost where applicable
Searcher: D. Schreiber	NA Sequence (#)	STN: 186.80
Searcher Phone #: 308-4292	AA Sequence (#)	Dialog:
Searcher Location: Cm1 CM03	Structure (#)	Questel/Orbit:
Date Searcher Picked Up:	Bibliographic: ✓	Dr. Link:
Date Completed: 9/16	Litigation	Lexis/Nexis:
Searcher Prep & Review Time: 14	Fulltext	Sequence Systems:
Clerical Prep Time:	Patent Family	WWW/Internet:
Online Time: 118	Other	Other (specify):

PTO-1590 (8-01)

t 3/14/4

3/14/4
DIALOG(R)File 452:Drug Data Report

AZ - 00198235
AA - 198235 (Preferred)
MF - C9H9N2O5P
CN - 4-(Phosphonomethyl)-1H- benzimidazole -2- carboxylic acid



ST - Biological Testing
OR - Pharmacia
TC - 12452 (Stroke, Treatment of)
12455 (NMDA Antagonists)
RE - 200776 (secondary)
200777 (secondary)
200778 (secondary)
200779 (secondary)
200780 (secondary)
200781 (secondary)
200782 (secondary)
200783 (secondary)
200784 (secondary)
200785 (secondary)
200786 (secondary)
200787 (secondary)
200788 (secondary)
200789 (secondary)
TX - ACTION: Agent for the treatment of neurotoxic injury associated with anoxia or ischemia following stroke, cardiac arrest or perinatalasphyxia; an NMDA receptor antagonist with a Ki = 1.6 mcM in the(3H)-glutamate binding assay, whereas Ki was > 100 mcM when using(3H)-kainate as the ligand. Significant in vivo antiischemic activity was demonstrated in a gerbil forebrain ischemia assay when givenintraperitoneally at doses of 300 and 500 mg/kg, 30 min prior tocarotid occlusion. Compound also exhibited anticonvulsant activity,as demonstrated by inhibiting electroconvulsive shock in mice and byprotecting against motor function impairment at a dose of 56 mg/kgs.c. A representative compound from a wide series of specificallyclaimed diacid-containing benzimidazole derivatives, wherein thefollowing are included:200776, 200777, 200778, 200779, 200780,200781, 200782, 200783,

200784, 200785, 200786, 200787, 200788,200789. (Drug Data Report, Vol. 15, No. 10, p. 907, 1993)
PU - Drug Data Report, Vol. 15, No. 10, p. 907, 1993
PI - DIACID-CONTAINING BENZIMIDAZOLE COMPOUNDS FOR TREATMENT OF NEUROTOXICINJURY
AUTHOR(s): Vazquez, M.L.
APPLICANT(s): Pharmacia
FAMILY: 5,216,003 [US 5216003] United States of America, June 1, 1993
PRIORITY: 2-816,207 [US 816207] United States of America, January 2, 1992

```
?e aa=315794

Ref    Items  Index-term
E1         1  AA=315792
E2         1  AA=315793
E3         1 *AA=315794
E4         1  AA=315795
E5         1  AA=315796
E6         1  AA=315803
E7         1  AA=315806
E8         1  AA=315807
E9         1  AA=315808
E10        1  AA=315809
E11        1  AA=315810
E12        1  AA=315811

          Enter P or PAGE for more
?s aa=315794
      S4       1  AA=315794
?t 4/14/1

 4/14/1
DIALOG(R)File 452:Drug Data Report
(c) 2003 Prous Science. All rts. reserv.
```

AZ - 00315794
AA - 315794 (Preferred)
MF - C11H8N6O5
CN - 5-(5-Amino-1,3,4-oxadiazol-2-yl)-6-methyl-7-nitroquinoxaline-2,3(1H,4H)-dione



ST - Biological Testing
OR - Pfizer
TC - 9200 (Cognition Disorders, Treatment of)
33456 (Ischemic Stroke, Treatment of)
12457 (AMPA Antagonists)
RE - 315795 (secondary)
TX - ACTION: Glutamate antagonist with in vitro activity against AMPAreceptors and the glycine site of NMDA receptors. Potentially usefulfor the treatment of cerebral ischemia, chronic neurodegenerativedisorders including Alzheimer's disease, Parkinson's disease andHuntington's disease, seizure disorders, schizophrenia, anxiety, pain and drug abuse. Another exemplified quinoxaline-2,3-dione derivative is:315795. (Drug Data Report, Vol. 24, No. 4, p. 313, 2002)
PU - Drug Data Report, Vol. 24, No. 4, p. 313, 2002
PI - CONFORMATIONALLY SEMI-CONSTRAINED QUINOXALINE 2,3-DIONES ASNEUROPROTECTIVE AGENTS
AUTHOR(s): Rafferty, M.F., Kornberg, B.E., Nikam, S.S.
APPLICANT(s): Pfizer
FAMILY: 6,340,758 [US 6340758] United States of America, January 22, 2002
PRIORITY: 2-46,626 [US 46626] United States of America, May 16, 1997
2-25,295 [US 25295] United States of America, February 13, 1998
2-199,627 [US 199627] United States of America, November 25, 1998

?s aa=225249
S5 1 AA=225249
?t 5/14/1

5/14/1
DIALOG(R)File 452:Drug Data Report

AZ - 00225249
AA - 225249 (Preferred)
MF - C12H9N3O
CN - 6-Phenylimidazo(1,2-a)pyrazin-8(7H)-one



ST - Biological Testing
OR - Aventis Pharma
TC - 9200 (Cognition Disorders, Treatment of)
11100 (Antiparkinsonian Drugs)
12452 (Stroke, Treatment of)

12455 (NMDA Antagonists)
12457 (AMPA Antagonists)
RE - 227609 (secondary)
227610 (secondary)
227611 (secondary)
227612 (secondary)
TX - ACTION: Noncompetitive antagonist at the glycine site of the NMDAreceptor, potentially useful for the treatment and prophylaxis ofcerebral ischemic/anoxic disorders, and for the treatment ofneurodegenerative disorders such as parkinsonism and Alzheimer'sdisease, as well as epilepsy, schizophrenia and migraine. Otherexemplified imidazopyrazinones include the following:227609, 227610,227611, 227612. (Drug Data Report, Vol. 17, No. 11, p. 989, 1995)
PU - Drug Data Report, Vol. 17, No. 11, p. 989, 1995
PI - 7H-IMIDAZO(1,2-A)PYRAZINE-8-ONE NMDA RECEPTOR ANTAGONISTS
AUTHOR(s): Aloup, J.-C., Mignani, S., Jimonet, P., Audiau, F., Damour, D., Genevois-Borella, A.
APPLICANT(s): Aventis Pharma
FAMILY: 0726900 [EP 0726900] European Patent Office, August 21, 1996
6-97504539 [JP 697504539]Japan, May 6, 1997
WO95-12594 [WO 9512594] W.I.P.O., May 11, 1995
PRIORITY: 13164 [FR 9313164] France, November 5, 1993
?s aa=240624
S6 1 AA=240624
?t 6/14/1

6/14/1
DIALOG(R)File 452:Drug Data Report

AZ - 00240624
AA - 240624 (Preferred)
MF - C18H10CL2N2O3
CN - 4,6-Dichloro-3-(N-phenylcarbamoylethynyl)-1H-indole-2-carboxylic acid
RN - 153436-32-9



ST - Preclinical
OR - GlaxoSmithKline
TC - 12452 (Stroke, Treatment of)
12455 (NMDA Antagonists)
TX - ACTION: An NMDA antagonist acting at the strychnine-insensitiveglycine binding site and structurally related to GV-150526, for usein the treatment of CNS disorders such as stroke, Huntington'sdisease, Alzheimer's disease and neurotrauma. Its affinity (pKi

=7.7) is inferior to that of GV-150526 (pKi = 8.5), but it displayedgood in vivo activity in mice against NMDA-induced convulsions (ED50= 0.2 mg/kg i.v.; ED50 GV-150526 = 0.06 mg/kg i.v.). (Drug Data Report, Vol. 18, No. 11, p. 966, 1996)
PU - Drug Data Report, Vol. 18, No. 11, p. 966, 1996
PI - INDOLE ANTAGONISTS OF EXCITATORY AMINO ACIDS
AUTHOR(s): Gaviraghi, G., Cugola, A.
APPLICANT(s): GlaxoSmithKline
FAMILY: 1006343 [BE 1006343] Belgium, July 26, 1994
685630 [CH 685630] Switzerland, August 31, 1995
0568136 [EP 0568136] European Patent Office, November 3, 1993
2105924 [ES 2105924] Spain, October 16, 1997
2690919 [FR 2690919] France, November 12, 1993
2266091 [GB 2266091] Great Britain, October 20, 1993
6-94049027 [JP 694049027] Japan, February 22, 1994
5,373,018 [US 5373018] United States of America, December 13, 1994
5,374,648 [US 5374648] United States of America, December 20, 1994
5,374,649 [US 5374649] United States of America, December 20, 1994
WO93-21153 [WO 9321153] W.I.P.O., October 28, 1993
PRIORITY: 928492 [GB 928492] Great Britain, April 16, 1992
RF - Di Fabio, R. et al., "3-Alkynyl-2-carboxyindoles as a novel class of antagonists acting atthe strychnine-insensitive glycine binding site", 14th Int Symp Med Chem (Sept 8-12, Maastricht) 1996, Abst P-6.17
?s aa=257448
S7 1 AA=257448
?t 7/14/1

7/14/1
DIALOG(R)File 452:Drug Data Report

AZ - 00257448
AA - 257448 (Preferred)
MF - C16H11N3O2
CN - 2-Phenyl-2,3,4,5-tetrahydro-1H-pyridazino(4,5-b)indole-1,4-dione



ST - Biological Testing
OR - Merck Sharp & Dohme
TC - 9200 (Cognition Disorders, Treatment of)
10000 (Antiepileptic Drugs)
11100 (Antiparkinsonian Drugs)

33456 (Ischemic Stroke, Treatment of)
12455 (NMDA Antagonists)
TX - ACTION: Selective and noncompetitive NMDA receptor antagonist thatpreferentially binds to the strychnine-insensitive glycine bindingsite associated with the NMDA receptor complex. Compound blocked theresponse to NMDA in rat cortex slices (Kb < 150 mcM) and displaced(3H)-L-689560 binding to the strychnine-insensitive site in ratforebrain membranes (IC50 < 50 mcM). Potentially useful in thetreatment or prevention of neurodegenerative disorders such asstroke, cerebral ischemia, epilepsy, Huntington's chorea, Alzheimer's disease, Parkinson's disease and anoxia. (Drug Data Report, Vol. 20, No. 2, p. 121, 1998)
PU - Drug Data Report, Vol. 20, No. 2, p. 121, 1998
PI - PYRIDAZINO-INDOLE DERIVATIVES
AUTHOR(s): Macleod, A.M., Ladduwahetty, T.
APPLICANT(s): Merck Sharp & Dohme
FAMILY: 5,693,640 [US 5693640] United States of America, December 2, 1997
PRIORITY: 9411955 [GB 9411955] Great Britain, June 15, 1994

```
?s phenylsulfanyl/cn
      S8      300  PHENYLSULFANYL/CN
?s s8 and quinolin
             300  S8
            2069  QUINOLIN
      S9       8  S8 AND QUINOLIN
?s s9 and chloro/cn
               8  S9
            9353  CHLORO/CN
     S10       4  S9 AND CHLORO/CN
?t 10/k/1-4

 10/K/1
DIALOG(R)File 452:(c) 2003 Prous Science. All rts. reserv.

CHEM NAME:     2-(3-(9- Chloro -4-oxo-3-( phenylsulfanyl )-4,5-dihydroisoxa
               zolo(4,3-c) quinolin -5-yl)phenyl)-N-(3,4,5-trimethoxyphenyl
               )acetamide


 10/K/2
DIALOG(R)File 452:(c) 2003 Prous Science. All rts. reserv.

CHEM NAME:     7- Chloro -4-hydroxy-3-( phenylsulfanyl ) quinolin -2(1H)-on
               e


 10/K/3
DIALOG(R)File 452:(c) 2003 Prous Science. All rts. reserv.

CHEM NAME:     1-(4- Chloro -3-( phenylsulfanyl ) quinolin -2-yl)-4-(2-naph
               thylmethyl)piperazine


 10/K/4
DIALOG(R)File 452:(c) 2003 Prous Science. All rts. reserv.

CHEM NAME:     N-(1-Benzylpiperidin-4-yl)-N-(4- chloro -3-( phenylsulfanyl
               ) quinolin -2-yl)amine
```

?t 10/14/2

10/14/2
DIALOG(R)File 452:Drug Data Report

AZ - 00269005
AA - 269005 (Preferred)
MF - C15H10CLNO2S
CN - 7- Chloro -4-hydroxy-3-(phenylsulfanyl) quinolin -2(1H)-one



ST - Biological Testing
OR - Korea Res. Inst. Chem. Technol.
TC - 12450 (Cerebrovascular Diseases, Treatment of)
12455 (NMDA Antagonists)
RE - 269006 (secondary)
269007 (secondary)
269008 (secondary)
269009 (secondary)
269010 (secondary)
269011 (secondary)
269012 (secondary)
269013 (secondary)
269014 (secondary)
269015 (secondary)
TX - ACTION: Potent and specific antagonist at the strychnine-insensitive glycine binding site on the NMDA receptor complex, reported topossess good CNS penetration and high solubility. Claimed for thetreatment or prevention of ischemic, hypoxic or hypoglycemic CNSdamage, neurodegenerative disorders such as Alzheimer's disease,Huntington's disease, Parkinson's disease, epilepsy and stroke, aswell as for use as an anticonvulsant, analgesic, antidepressant,anxiolytic and antipsychotic agent. A representative compound from aseries of quinolinic sulfide derivatives, wherein the following arealso included:269006, 269007, 269008, 269009, 269010, 269011, 269012, 269013, 269014, 269015. (Drug Data Report, Vol. 20, No. 11, p. 932, 1998)
PU - Drug Data Report, Vol. 20, No. 11, p. 932, 1998
PI - QUINOLINIC SULFIDE DERIVATIVES ACTING AS NMDA RECEPTOR ANTAGONISTS ANDPROCESS FOR PREPARATION THEREOF
AUTHOR(s): Kong, J.Y., Jung, Y.S., Lee, C.W., Choi, S.W., Park, N.S., Seong, C.M., Chon, J.I., Chung, Y.J., Park, W.K.
APPLICANT(s): Korea Res. Inst. Chem. Technol.
FAMILY: 0869122 [EP 0869122] European Patent Office, October 7, 1998
6-98310575 [JP 698310575]Japan, November 24, 1998

	5,990,126	[US 5990126]	United States of America, November 23, 1999
PRIORITY:	11958	[KR 9711958]	N/A, March 31, 1997
	13818	[KR 9713818]	N/A, April 15, 1997
	58546	[KR 9758546]	N/A, November 6, 1997

?